SHED is one of the newer telehealth GLP-1 programs generating strong patient feedback. Here's our full review of their pricing, process, and clinical quality.
SHED is a telehealth weight loss platform focused on medically supervised GLP-1 programs, including access to compounded semaglutide and related medications. The program positions itself around a streamlined, patient-friendly experience — faster onboarding than traditional clinical programs while maintaining appropriate clinical oversight.
The name itself signals the brand positioning: SHED is about results, not bureaucracy. And based on patient feedback and our editorial review, they largely deliver on that promise.
SHED's pricing sits competitively within the market for compounded GLP-1 programs. Based on current program information:
Verify current pricing directly with SHED, as rates can change. The value proposition remains consistent: meaningful savings versus branded alternatives with comparable clinical outcomes when properly dosed.
This is the right question to ask about any compounded GLP-1 program, and SHED's answer is solid. Their pharmacy partners maintain compounding standards that include sterility testing and potency verification — the markers that distinguish professional compounding from the low-quality programs that give the industry a bad name.
SHED requires patients to meet standard GLP-1 eligibility criteria — typically BMI ≥30, or ≥27 with qualifying comorbidities. This isn't just legal compliance; it's the clinical standard that ensures patients are actually appropriate candidates for this class of medication.
Patient reports about SHED cluster around a few consistent themes:
The most common complaint mirrors industry-wide patterns: nausea at higher doses, which resolves when patients titrate more slowly. SHED's clinical team appears to proactively advise slower titration based on patient accounts.
Compared to larger, more established telehealth platforms, SHED punches above its weight on responsiveness and patient experience. The onboarding is faster than many legacy programs, and the clinical quality appears to be on par with the best providers in this space. Where it lags slightly is brand recognition — patients newer to GLP-1 telehealth programs may not have heard of SHED, which affects trust signals during the research phase.
That said, patients who've done their homework consistently rank SHED among their top choices.
SHED is a strong fit for:
SHED earns a strong recommendation. The combination of clinical rigor, competitive pricing, and faster-than-average onboarding makes it one of the more attractive options in a crowded market. If Synergy Rx is the gold standard for patients who want maximum accreditation certainty, SHED is the top choice for patients who want clinical quality with a faster, more modern patient experience.
Start your intake assessment today. Most patients receive a decision within 24 hours of submitting their health history.
Visit SHED →Affiliate disclosure: We earn a commission if you purchase through this link, at no extra cost to you.